Cargando…

Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway

PURPOSE: The ‘Outcomes & Multi-morbidity in Type 2 Diabetes’ (OMIT) is an observational registry-based cohort of Norwegian patients with type 2 diabetes (T2D) established to study high-risk groups often omitted from randomised clinical trials. PARTICIPANTS: The OMIT cohort includes 57 572 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Forster, Rachel B, Strandberg, Ragnhild B, Bø Tibballs, Katrina Louise, Nøkleby, Kjersti, Berg, Tore Julsrud, Iversen, Tor, Hagen, Terje P, Richardsen, Kåre Rønn, Cooper, John, Sandberg, Sverre, Løvaas, Karianne Fjeld, Nilsen, Roy Miodini, Iversen, Marjolein Memelink, Jenum, Anne Karen, Buhl, Esben Selmer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096542/
https://www.ncbi.nlm.nih.gov/pubmed/35545387
http://dx.doi.org/10.1136/bmjopen-2021-054840
_version_ 1784705999437824000
author Forster, Rachel B
Strandberg, Ragnhild B
Bø Tibballs, Katrina Louise
Nøkleby, Kjersti
Berg, Tore Julsrud
Iversen, Tor
Hagen, Terje P
Richardsen, Kåre Rønn
Cooper, John
Sandberg, Sverre
Løvaas, Karianne Fjeld
Nilsen, Roy Miodini
Iversen, Marjolein Memelink
Jenum, Anne Karen
Buhl, Esben Selmer
author_facet Forster, Rachel B
Strandberg, Ragnhild B
Bø Tibballs, Katrina Louise
Nøkleby, Kjersti
Berg, Tore Julsrud
Iversen, Tor
Hagen, Terje P
Richardsen, Kåre Rønn
Cooper, John
Sandberg, Sverre
Løvaas, Karianne Fjeld
Nilsen, Roy Miodini
Iversen, Marjolein Memelink
Jenum, Anne Karen
Buhl, Esben Selmer
author_sort Forster, Rachel B
collection PubMed
description PURPOSE: The ‘Outcomes & Multi-morbidity in Type 2 Diabetes’ (OMIT) is an observational registry-based cohort of Norwegian patients with type 2 diabetes (T2D) established to study high-risk groups often omitted from randomised clinical trials. PARTICIPANTS: The OMIT cohort includes 57 572 patients with T2D identified via linkage of Norwegian Diabetes Register for Adults and the Rogaland-Oslo-Salten-Akershus-Hordaland study, both offering data on clinical patient characteristics and drug prescriptions. Subsequently these data are further linked to the Norwegian Prescription Database for dispensed medications, the Norwegian Population Register for data on death and migration, Statistics Norway for data on socioeconomic factors and ethnicity and the Norwegian Directorate of Health for data on the general practices and clinical procedures involved in the care of cohort patients. OMIT offers large samples for key high-risk patient groups: (1) young-onset diabetes (T2D at age <40 years) (n=6510), (2) elderly (age >75 years) (n=15 540), (3) non-Western ethnic minorities (n=9000) and (4) low socioeconomic status (n=20 500). FINDINGS TO DATE: On average, patient age and diabetes duration is 67.4±13.2 and 12.3±8.3 years, respectively, and mean HbA(1c) for the whole cohort through the study period is 7.6%±1.5% (59.4±16.3 mmol/mol), mean body mass index (BMI) and blood pressure is 30.2±5.9 kg/m(2) and 135±16.1/78±9.8 mm Hg, respectively. Prevalence of retinopathy, coronary heart disease and stroke is 10.1%, 21% and 6.7%, respectively. FUTURE PLANS: The OMIT cohort features 5784 subjects with T2D in 2006, a number that has grown to 57 527 in 2019 and is expected to grow further via repeated linkages performed every third to fifth year. At the next wave of data collection, additional linkages to Norwegian Patient Registry and Norwegian Cause of Death Registry for data on registered diagnoses and causes of death, respectively, will be performed.
format Online
Article
Text
id pubmed-9096542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90965422022-05-18 Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway Forster, Rachel B Strandberg, Ragnhild B Bø Tibballs, Katrina Louise Nøkleby, Kjersti Berg, Tore Julsrud Iversen, Tor Hagen, Terje P Richardsen, Kåre Rønn Cooper, John Sandberg, Sverre Løvaas, Karianne Fjeld Nilsen, Roy Miodini Iversen, Marjolein Memelink Jenum, Anne Karen Buhl, Esben Selmer BMJ Open Diabetes and Endocrinology PURPOSE: The ‘Outcomes & Multi-morbidity in Type 2 Diabetes’ (OMIT) is an observational registry-based cohort of Norwegian patients with type 2 diabetes (T2D) established to study high-risk groups often omitted from randomised clinical trials. PARTICIPANTS: The OMIT cohort includes 57 572 patients with T2D identified via linkage of Norwegian Diabetes Register for Adults and the Rogaland-Oslo-Salten-Akershus-Hordaland study, both offering data on clinical patient characteristics and drug prescriptions. Subsequently these data are further linked to the Norwegian Prescription Database for dispensed medications, the Norwegian Population Register for data on death and migration, Statistics Norway for data on socioeconomic factors and ethnicity and the Norwegian Directorate of Health for data on the general practices and clinical procedures involved in the care of cohort patients. OMIT offers large samples for key high-risk patient groups: (1) young-onset diabetes (T2D at age <40 years) (n=6510), (2) elderly (age >75 years) (n=15 540), (3) non-Western ethnic minorities (n=9000) and (4) low socioeconomic status (n=20 500). FINDINGS TO DATE: On average, patient age and diabetes duration is 67.4±13.2 and 12.3±8.3 years, respectively, and mean HbA(1c) for the whole cohort through the study period is 7.6%±1.5% (59.4±16.3 mmol/mol), mean body mass index (BMI) and blood pressure is 30.2±5.9 kg/m(2) and 135±16.1/78±9.8 mm Hg, respectively. Prevalence of retinopathy, coronary heart disease and stroke is 10.1%, 21% and 6.7%, respectively. FUTURE PLANS: The OMIT cohort features 5784 subjects with T2D in 2006, a number that has grown to 57 527 in 2019 and is expected to grow further via repeated linkages performed every third to fifth year. At the next wave of data collection, additional linkages to Norwegian Patient Registry and Norwegian Cause of Death Registry for data on registered diagnoses and causes of death, respectively, will be performed. BMJ Publishing Group 2022-05-11 /pmc/articles/PMC9096542/ /pubmed/35545387 http://dx.doi.org/10.1136/bmjopen-2021-054840 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Diabetes and Endocrinology
Forster, Rachel B
Strandberg, Ragnhild B
Bø Tibballs, Katrina Louise
Nøkleby, Kjersti
Berg, Tore Julsrud
Iversen, Tor
Hagen, Terje P
Richardsen, Kåre Rønn
Cooper, John
Sandberg, Sverre
Løvaas, Karianne Fjeld
Nilsen, Roy Miodini
Iversen, Marjolein Memelink
Jenum, Anne Karen
Buhl, Esben Selmer
Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway
title Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway
title_full Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway
title_fullStr Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway
title_full_unstemmed Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway
title_short Cohort profile: Outcomes & Multi-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway
title_sort cohort profile: outcomes & multi-morbidity in type 2 diabetes (omit) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in norway
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096542/
https://www.ncbi.nlm.nih.gov/pubmed/35545387
http://dx.doi.org/10.1136/bmjopen-2021-054840
work_keys_str_mv AT forsterrachelb cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT strandbergragnhildb cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT bøtibballskatrinalouise cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT nøklebykjersti cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT bergtorejulsrud cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT iversentor cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT hagenterjep cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT richardsenkarerønn cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT cooperjohn cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT sandbergsverre cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT løvaaskariannefjeld cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT nilsenroymiodini cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT iversenmarjoleinmemelink cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT jenumannekaren cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway
AT buhlesbenselmer cohortprofileoutcomesmultimorbidityintype2diabetesomitanationalregistrybasedobservationalcohortwithfocusoncareandtreatmentofkeyhighriskgroupsinnorway